公开(公告)号：WO2023041375A1

公开(公告)日：2023-03-23

申请号：PCT/EP2022/074724

申请日：2022-09-06

Applicant: LTS LOHMANN THERAPIE-SYSTEME AG

Inventor： SEIBERTZ, Frank ,  BAUER, Marius ,  FUHRMANN, Marlene ,  LINN, Michael ,  EMGENBROICH, Marco

IPC: A61K9/00 ,  A61K31/135 ,  A61K31/485 ,  A61K31/495 ,  A61K31/57 ,  A61P15/18 ,  A61P25/04 ,  A61P25/24 ,  A61P25/36

Abstract: Beschrieben wird ein oraler dünner Film, umfassend mindestens eine Matrixschicht, wobei die mindestens eine Matrixschicht mindestens einen Polyvinylalkohol mit einem niedrigeren mittleren Molekulargewicht und mindestens einen Polyvinylalkohol mit einem höheren mittleren Molekulargewicht und mindestens einen pharmazeutischen Wirkstoff umfasst, und dessen Verwendung als Arzneimittel.

公开(公告)号：WO2023031955A1

公开(公告)日：2023-03-09

申请号：PCT/IN2022/050765

申请日：2022-08-29

Applicant: REDASANI, Vijayendrakumar Virendrakumar Ji

Inventor： KHABIYA, Shantilal Prakashchand ,  BALAKSHE, Prajkta Vitthal

IPC: A61K31/485 ,  A61P1/00 ,  A61K9/00

Abstract: The present invention relates to solid oral pharmaceutical compositions of methylnaltrexone and its salts. The compositions are free of an ion pairing agent and particularly free of sodium lauryl sulphate. The compositions contain a solid solubilizer and / or a semi-solid low melting solubilizer which enhances solubility of the compositions and thereby gastrointestinal absorption of such compositions.

公开(公告)号：WO2023020608A1

公开(公告)日：2023-02-23

申请号：PCT/CN2022/113527

申请日：2022-08-19

Applicant: 苏州恩华生物医药科技有限公司 ,  江苏恩华药业股份有限公司

Inventor： 李雄 ,  施能静 ,  董达文 ,  储开慧 ,  陈晶 ,  赫侠平 ,  蒋钰 ,  卜淼淼 ,  周珺

IPC: A61K9/107 ,  A61K31/485 ,  A61K47/10 ,  A61K47/26 ,  A61K47/28 ,  A61K47/44 ,  A61P25/04

Abstract: 一种包含塞纳布啡的药物组合物，以及其制备方法和应用。所述药物组合物包含酰基甘油、磷脂酰胆碱、至少一种含氧有机溶剂、至少一种酸和塞纳布啡，所得到的药物组合物稳定性更高，起效更快，作用时间更长，并能降低注射疼痛和减少溶血发生。

公开(公告)号：WO2023004064A1

公开(公告)日：2023-01-26

申请号：PCT/US2022/037913

申请日：2022-07-21

Applicant: ANTECIP BIOVENTURES II LLC

Inventor： TABUTEAU, Herriot

IPC: A61K31/137 ,  A61K31/485 ,  A61K9/00 ,  A61K9/24 ,  A61P25/24

Abstract: This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of dextromethorphan; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan for treating depression in patients with certain levels of dextromethorphan.

公开(公告)号：WO2022269266A1

公开(公告)日：2022-12-29

申请号：PCT/GB2022/051608

申请日：2022-06-23

Applicant: LDN PHARMA LIMITED

Inventor： LIU, Wai ,  THOMPSON, Ian ,  HOOD, Francis

IPC: A61K31/485 ,  A61K31/675 ,  A61K31/135 ,  A61K31/36 ,  A61K31/48 ,  A61K45/06 ,  A61P25/28

Abstract: A composition comprising an agonist of a 5-hydroxytryptamine (5-HT) receptor subtype 2A, 2B or 2C (5-HT2A, 5-HT2B or 5-HT2C), for the use in the treatment of a cognitive or neurological disorder in a patient, said patient having been pre- treated with naltrexone, or a metabolite thereof or an analogue selected from the group consisting of methylnaltrexone, nalmefene and nalorphine.

公开(公告)号：WO2022251683A1

公开(公告)日：2022-12-01

申请号：PCT/US2022/031411

申请日：2022-05-27

Applicant: ALLEN, Gregory Seth

Inventor： ALLEN, Gregory Seth

IPC: A61K31/137 ,  A61K31/4985 ,  A61K31/485 ,  A61P3/04

Abstract: The disclosure relates to compositions comprising a phentermine and a unicyclic aminoketone and methods of use thereof. The methods of use include inducing weight loss or reducing weight gain in a human subject. The unicyclic aminoketone may be diethylpropion or bupropion. In some embodiments, the compositions further include tadalafil or naltrexone.

公开(公告)号：WO2022198167A1

公开(公告)日：2022-09-22

申请号：PCT/US2022/070941

申请日：2022-03-03

Applicant: OAKWOOD LABORATORIES, LLC

Inventor： MINROVIC, Bradley ,  STRAIGHT, Emma ,  ZEMANSKI, Kaitlin ,  RICHEY, Tracy

IPC: A61K31/337 ,  A61K31/485 ,  A61K31/513

Abstract: Microsphere formulations comprising naltrexone are provided. The microsphere formulations comprise polymer microspheres, each polymer microsphere comprising: (i) naltrexone; and (ii) a biodegradable polymer comprising a POE or a PLA, wherein each polymer microsphere comprises a drug load of naltrexone of at least 40% by weight of the polymer microsphere, and wherein the polymer microspheres have an average particle size of about 25 mm to about 55 mm (D50). Methods for making and using the microsphere formulations are also provided.

公开(公告)号：WO2022194022A1

公开(公告)日：2022-09-22

申请号：PCT/CN2022/080164

申请日：2022-03-10

Applicant: 苏州恩华生物医药科技有限公司 ,  江苏恩华药业股份有限公司

Inventor： 张玲 ,  蒋钰 ,  陈帅 ,  蔡兆雄

IPC: C07D489/02 ,  C07D489/09 ,  A61K31/485 ,  A61P25/04

Abstract: 一种纳布啡癸二酸酯及其中间体的制备方法，利用该方法可高效、便捷、安全的制备得到纳布啡癸二酸酯，显著提高终产品纳布啡癸二酸酯的纯度和收率。

公开(公告)号：WO2022191615A1

公开(公告)日：2022-09-15

申请号：PCT/KR2022/003317

申请日：2022-03-08

Applicant: (주)인벤티지랩

Inventor： 김주희 ,  이마세 ,  김동훈

IPC: A61K9/16 ,  A61K9/00 ,  A61K31/485 ,  A61P37/00

Abstract: 날트렉손(naltrexone) 또는 그의 약학적으로 허용가능한 염, 및 생분해성 고분자를 포함하는 마이크로입자를 포함하는 자가면역질환 예방 또는 치료용 서방성 제제 및 이를 이용한 방법을 제공한다. 이에 따르면, 자가면역질환을 1회 투여로 장기지속적으로 예방 또는 치료하는데 이용할 수 있다.

公开(公告)号：WO2022155591A1

公开(公告)日：2022-07-21

申请号：PCT/US2022/012768

申请日：2022-01-18

Applicant: ANTECIP BIOVENTURES II LLC

Inventor： TABUTEAU, Herriot

IPC: A61K31/137 ,  A61K31/485 ,  A61P25/24

Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, is orally administered to a human being to be treated with, or being treated with, dextromethorphan.